Artificial intelligence-based segmentation of residual tumor in histopathology of pancreatic cancer after neoadjuvant treatment

Boris V. Janssen, Rutger Theijse, Stijn van Roessel, Rik de Ruiter, Antonie Berkel, Joost Huiskens, Olivier R. Busch, Johanna W. Wilmink, Geert Kazemier, Pieter Valkema, Arantza Farina, Joanne Verheij, Onno J. de Boer, Marc G. Besselink

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)

Abstract

BACKGROUND: Histologic examination of resected pancreatic cancer after neoadjuvant therapy (NAT) is used to assess the effect of NAT and may guide the choice for adjuvant treatment. However, evaluating residual tumor burden in pancreatic cancer is challenging given tumor response heterogeneity and challenging histomorphology. Artificial intelligence techniques may offer a more reproducible approach.

METHODS: From 64 patients, one H&E-stained slide of resected pancreatic cancer after NAT was digitized. Three separate classes were manually outlined in each slide (i.e., tumor, normal ducts, and remaining epithelium). Corresponding segmentation masks and patches were generated and distributed over training, validation, and test sets. Modified U-nets with varying encoders were trained, and F1 scores were obtained to express segmentation accuracy.

RESULTS: The highest mean segmentation accuracy was obtained using modified U-nets with a DenseNet161 encoder. Tumor tissue was segmented with a high mean F1 score of 0.86, while the overall multiclass average F1 score was 0.82.

CONCLUSIONS: This study shows that artificial intelligence-based assessment of residual tumor burden is feasible given the promising obtained F1 scores for tumor segmentation. This model could be developed into a tool for the objective evaluation of the response to NAT and may potentially guide the choice for adjuvant treatment.

Original languageEnglish
Article number5089
JournalCancers
Volume13
Issue number20
DOIs
Publication statusPublished - 12 Oct 2021

Keywords

  • Artificial intelligence
  • Histopathology
  • Machine learning
  • Neoadjuvant therapy
  • Pancreatic cancer
  • Tumor response scoring

Cite this